Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico.

ABSTRACT:

Aims

To evaluate the safety and effectiveness of iGlarLixi in people with type 2 diabetes mellitus (T2DM) in clinical practice in Mexico.

Materials and methods

This was a prospective, observational, multicentre study in adults with T2DM who were prescribed iGlarLixi in routine clinical practice in Mexico. The participants were followed for 24 ± 1 months. The primary endpoint included the incidence proportion, incidence rate of adverse drug reactions (ADRs), serious ADRs and the severity of suspected ADRs possibly related to iGlarLixi throughout the study.

Results

The study included 330 participants (mean ± SD age: 57.8 ± 11.9 years, weight: 77.1 ± 17.7 kg, duration of diabetes: 14.1 ± 9.9 years, and female: 55.5%). During the 24-month study, 59 participants (17.9%; 95

SUBMITTER: Rosas-Guzman J 

PROVIDER: S-EPMC12046447 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature